Dilation of a sigma stenosis with a stent
Video report of live endoscopies performed at the Endo Club Nord 2013 in Hamburg, November 1 – 2, 2013. © Dr. Falk Pharma GmbH, Freiburg.
Video recording of the dilation of 6 cm sigmoid stenosis caused by a carcinoma by placing a stent. The procedure was performed during Endo Club Nord 2013 by PD. Dr. Siegbert Faiss, Asklepios Hospital Barmbek.
Please switch on your loudspeakers!
Link to Falk Mediacenter:
Link to the video directly:
180 x 112 pixels
580 x 350 pixels
Billioud V et al, J Crohns Colitis. 2013;7(11):853–67
Preoperative anti-TNF use slightly increases the occurrence of overall postoperative complications in inflammatory bowel disease patients, and particularly infectious complications in Crohn’s disease patients. Postoperative complications are not increased in ulcerative colitis.
Khan N et al, Gastroenterology. 2013;145(5):1007–15
Based on a retrospective, nationwide cohort study in the US, patients with ulcerative colitis have a 4-fold increase in risk of lymphoma while being treated with thiopurines compared with patients who have not been treated with thiopurines. The risk increases gradually for successive years of therapy. Discontinuing thiopurine therapy reduces the risk of lymphoma.
Sandborn WJ et al, Gastroenterology. 2014;146(1):85–95
Sandborn WJ et al, Gastroenterology. 2014;146(1):96–109
Treatment with subcutaneous golimumab (100 mg/50 mg/50 mg, or 200 mg/100 mg/100 mg, or 400 mg/200 mg/200 mg, 2 weeks apart) induces clinical response (51–54% vs. 30% for placebo), remission, and mucosal healing at week 6, and increases quality of life in larger percentages of patients with active ulcerative colitis than placebo. Golimumab (50 mg or 100 mg) maintained clinical response through week 54 in patients who had responded to induction therapy with golimumab and had moderate-to-severe active ulcerative colitis; patients who received 100 mg golimumab had clinical remission and mucosal healing at weeks 30 and 54. Safety was consistent with that reported for other TNF-α antagonists and golimumab in other approved indications.
Karkhanis J et al, Hepatology. 2014;59(2):612–21
Corticosteroids did not improve overall survival or spontaneous survival in drug-induced, indeterminate, or autoimmune acute liver failure and were associated with lower survival in patients with the highest MELD scores.
Fried MW et al, Hepatology. 2013;58(6):1918–29
Simeprevir administered once-daily in combination with pegylated interferon-α2a and ribavirin significantly improves the sustained virologic response rates, compared with pegylated interferon-α2a and ribavirin alone, and allows the majority of patients to shorten their therapy duration to 24 weeks.
Kitrinos KM et al, Hepatology. 2014;59(2):434–42
Tenofovir disoproxil fumarate monotherapy maintains effective suppression of HBV DNA through 288 weeks of treatment with no evidence of resistance to the drug.
Bae SE et al, Am J Gastroenterol. 2014;109(1):60–7
Successful Helicobacter pylori eradication may reduce the occurrence of metachronous gastric cancer after endoscopic resection in patients with early gastric cancer.
Singh S et al, Clin Gastroenterol Hepatol. 2013;11(11):1399–412
Central adiposity, independent of body mass index, is associated with esophageal inflammation (erosive esophagitis), metaplasia (Barrett’s esophagus), and neoplasia (esophageal adenocarcinoma). Its effects are mediated by reflux-dependent and reflux-independent mechanisms.
McNicholl AG et al, Gut. 2014;63(2):244–9
10 days concomitant therapy of infection with Helicobacter pylori with omeprazole, amoxicillin, clarithromycin, and metronidazole led to a slightly better eradication rate of 91% than sequential therapy with the same substances (86%). Both therapies showed an acceptable safety profile.
Bhoo-Pathy N et al, Clin Gastroenterol Hepatol. 2013;11(11):1486–92
Based on an analysis of data from the European Prospective Investigation into Nutrition and Cancer cohort, total coffee, decaffeinated coffee, and tea consumption are not related to the risk of pancreatic cancer.
Current Falk literature:
What you should know about gallstone treatment
Compiled by: M. Sackmann
Order by email (Please replace text by your email address):